US11123405B2 - Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions - Google Patents

Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions Download PDF

Info

Publication number
US11123405B2
US11123405B2 US16/065,445 US201616065445A US11123405B2 US 11123405 B2 US11123405 B2 US 11123405B2 US 201616065445 A US201616065445 A US 201616065445A US 11123405 B2 US11123405 B2 US 11123405B2
Authority
US
United States
Prior art keywords
administration
glp
agonist
disease
nly001
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/065,445
Other languages
English (en)
Other versions
US20180369340A1 (en
Inventor
Seulki Lee
Ted M. Dawson
Han Seok Ko
Valina L. Dawson
Seung Pil Yun
Magdalena Scully
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to US16/065,445 priority Critical patent/US11123405B2/en
Assigned to THE JOHNS HOPKINS UNIVERSITY reassignment THE JOHNS HOPKINS UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SWIERCZEWSKA, MAGDALENA, Yun, Seung Pil, DAWSON, TED M., DAWSON, VALINA L., KO, HAN SEOK, LEE, SEULKI
Publication of US20180369340A1 publication Critical patent/US20180369340A1/en
Assigned to THE JOHNS HOPKINS UNIVERSITY reassignment THE JOHNS HOPKINS UNIVERSITY CORRECTIVE ASSIGNMENT TO CORRECT THE LAST IVENTORS NAME SHOULD BE MAGDALENA SCULLY PREVIOUSLY RECORDED AT REEL: 046509 FRAME: 0457. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: SCULLY, MAGDALENA, Yun, Seung Pil, DAWSON, TED M., DAWSON, VALINA L., KO, HAN SEOK, LEE, SEULKI
Application granted granted Critical
Publication of US11123405B2 publication Critical patent/US11123405B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
US16/065,445 2015-12-23 2016-12-22 Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions Active US11123405B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/065,445 US11123405B2 (en) 2015-12-23 2016-12-22 Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387319P 2015-12-23 2015-12-23
US16/065,445 US11123405B2 (en) 2015-12-23 2016-12-22 Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions
PCT/US2016/068378 WO2017112889A1 (fr) 2015-12-23 2016-12-22 Agoniste de glp-1r à action prolongée pour la thérapie de troubles neurologiques et neurodégénératifs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/068378 A-371-Of-International WO2017112889A1 (fr) 2015-12-23 2016-12-22 Agoniste de glp-1r à action prolongée pour la thérapie de troubles neurologiques et neurodégénératifs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/479,428 Continuation US20220111010A1 (en) 2015-12-23 2021-09-20 Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions

Publications (2)

Publication Number Publication Date
US20180369340A1 US20180369340A1 (en) 2018-12-27
US11123405B2 true US11123405B2 (en) 2021-09-21

Family

ID=59091242

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/065,445 Active US11123405B2 (en) 2015-12-23 2016-12-22 Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions
US17/479,428 Pending US20220111010A1 (en) 2015-12-23 2021-09-20 Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/479,428 Pending US20220111010A1 (en) 2015-12-23 2021-09-20 Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions

Country Status (13)

Country Link
US (2) US11123405B2 (fr)
EP (1) EP3393496B1 (fr)
JP (2) JP7026044B2 (fr)
KR (1) KR102508651B1 (fr)
CN (1) CN108697768B (fr)
AU (1) AU2016379403B2 (fr)
CA (1) CA3009506A1 (fr)
DK (1) DK3393496T3 (fr)
EA (1) EA201891469A1 (fr)
ES (1) ES2968038T3 (fr)
LT (1) LT3393496T (fr)
PL (1) PL3393496T3 (fr)
WO (1) WO2017112889A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220273769A1 (en) * 2019-07-29 2022-09-01 Peptron, Inc. Pharmaceutical composition for treating levodopa-induced dyskinesia or for sup-pressing progression thereof
KR102552385B1 (ko) * 2019-07-29 2023-07-06 주식회사 펩트론 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물
CA3154744A1 (fr) * 2019-11-06 2021-05-14 Sarah FRIEDRICH Agonistes du recepteur glp-1 dans la demence
AU2021399517A1 (en) * 2020-12-16 2023-07-06 The Chinese University Of Hong Kong A method for reversing aging brain functional decline
CN113350488B (zh) * 2021-07-16 2023-07-14 中国药科大学 口服降糖肽ohp在制备抗神经退行性疾病药物方面的应用
WO2023028554A1 (fr) * 2021-08-25 2023-03-02 Neuraly, Inc. Agonistes de glp-1r destinés à être utilisés dans le traitement d'une déficience neurologique associée à une infection virale
WO2023228155A1 (fr) * 2022-05-27 2023-11-30 D&D Pharmatech Inc. Compositions et méthodes de traitement de troubles neurologiques

Citations (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069911A1 (fr) 1999-05-17 2000-11-23 Conjuchem, Inc. Peptides insulinotropes a longue duree d'action
EP1137666A1 (fr) 1998-12-07 2001-10-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues glp-1
KR20020001719A (ko) 1999-01-14 2002-01-09 마크 엠. 폴렛타 글루카곤 억제 방법
WO2002016430A2 (fr) 2000-08-24 2002-02-28 Thomas Jefferson University Nouveau peptide possedant des effets sur la sante cerebrale
WO2003011892A2 (fr) 2001-07-31 2003-02-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendine-4, analogues peptidiques et utilisations associees
WO2004022004A2 (fr) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation
US20050009742A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
WO2005023862A2 (fr) 2003-08-07 2005-03-17 Zymogenetics, Inc. Preparations homogenes d'il-28 et d'il-29
WO2005077042A2 (fr) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Proteines hybrides d'albumine
US20050222036A1 (en) 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
EP1594529A2 (fr) 2003-02-19 2005-11-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Analogues de glp-1
WO2006042848A2 (fr) 2004-10-18 2006-04-27 Novo Nordisk A/S Conjugues d'hormones de croissance
US20060286066A1 (en) 2003-06-30 2006-12-21 Domantis Limited Pegylated immunoglobulin variable region polypeptides
EP1767545A1 (fr) 2005-09-22 2007-03-28 Biocompatibles UK Limited Polypeptides de fusion de glp-1 (peptide 1 de type glucagon) ayant une resistance accrue a la peptidase
WO2007075534A2 (fr) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Conjugues polymeres de glp-1
EP1854455A1 (fr) 2006-05-10 2007-11-14 Biocompatibles UK Limited Microcapsules sphériques contenant des peptides du type GLP-1, leur production et leur utilisation
KR20070115602A (ko) 2006-06-01 2007-12-06 이강춘 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도
CN101195612A (zh) 2006-12-05 2008-06-11 中国科学院上海药物研究所 一类具有取代环丁烷结构的化合物、及其制备方法和医学用途
WO2008130066A1 (fr) 2007-04-20 2008-10-30 Kang Choon Lee Exendine mono-modifiee par polyethylene glycol ou ses derives et utilisations associees
WO2008148839A2 (fr) 2007-06-08 2008-12-11 Ascendis Pharma As Conjugués polymères transitoires longue durée de l'exendine
EP2057189A1 (fr) 2006-08-25 2009-05-13 Novo Nordisk A/S Composés d'exendine-4 acylée
WO2010080578A1 (fr) 2008-12-18 2010-07-15 Phasebio Pharmaceuticals, Inc. Protéines biologiquement actives pouvant être activées par peptidase
WO2010121559A1 (fr) 2009-04-23 2010-10-28 派格生物医药(苏州)有限公司 Nouveau variant d'exendine et son conjugué
US20100323956A1 (en) 2009-02-03 2010-12-23 Amunix, Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011003007A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azabicycloalcane-indole et d’azabicycloalcane-pyrrolo-pyridine, procédés de préparation, et utilisation de ceux-ci
WO2011000095A1 (fr) 2009-07-02 2011-01-06 Angiochem Inc. Conjugués peptidiques multimères et leurs utilisations
KR20110007362A (ko) 2009-07-16 2011-01-24 성균관대학교산학협력단 엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법
WO2011075393A2 (fr) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
WO2011143209A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone
WO2012000118A1 (fr) 2010-07-02 2012-01-05 Angiochem Inc. Polypeptides courts contenant des acides aminés d pour conjugués thérapeutiques et leurs utilisations
WO2012012352A2 (fr) 2010-07-19 2012-01-26 Amidebio, Llc Peptides et protéines modifiés
AU2012202972A1 (en) 2005-09-22 2012-06-14 Biocompatibles Uk Ltd GLP-1 fusion peptides, their production and use
EP2505941A1 (fr) 2009-11-25 2012-10-03 Daikin Industries, Ltd. Dispositif de réfrigération pour contenant
WO2012177444A2 (fr) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon et du récepteur du gpl-1
WO2013002580A2 (fr) 2011-06-28 2013-01-03 정재경 Analogue d'exendine-4 pégylé par du polyéthylène glycol ou un dérivé de celui-ci, son procédé de préparation et composition pharmaceutique pour prévenir ou traiter le diabète, le contenant en tant que principe actif
WO2013004983A1 (fr) 2011-07-04 2013-01-10 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
WO2013009545A1 (fr) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Polypeptides génétiquement modifiés ayant une durée d'action accrue avec une immunogénéicité réduite
EP2578599A1 (fr) 2011-10-07 2013-04-10 LanthioPep B.V. Analogues cycliques de GLP-1 et peptides de type GLP-1
AU2013201640A1 (en) 2006-04-14 2013-04-11 Mannkind Corporation Glucagon-like peptide 1(GLP-1) pharmaceutical formulations
US20130116172A1 (en) 2010-05-13 2013-05-09 Marcadia Biotech, Inc. Glucagon superfamily peptides exhbiting g protein coupled receptor activity
US20130116179A1 (en) 2011-09-01 2013-05-09 University Of Ulster Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130157934A1 (en) 2011-11-17 2013-06-20 Indiana University Research And Technology Corporation Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity
EP2621538A2 (fr) 2010-09-28 2013-08-07 Amylin Pharmaceuticals, LLC Polypeptides génétiquement modifiés ayant une durée d'action renforcée
EP2630965A1 (fr) 2012-02-24 2013-08-28 Curatis Pharma GmbH Polypeptide pour la protection contre la neurodégénérescence chez les patients souffrant de la sclérose latérale amyotrophique
WO2013148966A1 (fr) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Administration transmuqueuse de polypeptides génétiquement modifiés
WO2013148871A1 (fr) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Polypeptides génétiquement modifiés
US20130281373A1 (en) 2010-05-05 2013-10-24 Boehringer Ingelheim International Gmbh Combination therapy
US20130303436A1 (en) 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
WO2013192130A1 (fr) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogues du glucagon présentant une activité sur le récepteur du gip
WO2014036323A1 (fr) 2012-08-29 2014-03-06 Mannkind Corporation Méthode et composition pour traiter l'hyperglycémie
WO2014041375A1 (fr) 2012-09-17 2014-03-20 Imperial Innovations Limited Analogues peptidiques du glucagon et du glp1
WO2014096145A1 (fr) 2012-12-21 2014-06-26 Sanofi Dérivés de l'exendine 4 utilisés comme agonistes de glp1/gip ou de glp1/gip/glucagon
US20140187490A1 (en) 2009-08-07 2014-07-03 Rose Pharma A/S Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome
WO2014110090A1 (fr) 2013-01-08 2014-07-17 Jerome Schentag Activation de la voie de l'hormone endogène du frein iléal pour la régénérescence d'un organe et des compositions associées, méthodes de traitement, diagnostics, et systèmes de régulation
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
WO2014131815A1 (fr) 2013-03-01 2014-09-04 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Peptides pour utilisation dans le traitement topique de maladies neurodégénératives rétiniennes, en particulier à des stades précoces de la rétinopathie diabétique et d'autres maladies rétiniennes dans lesquelles la neurodégénérescence joue un rôle essentiel
WO2014152795A2 (fr) 2013-03-14 2014-09-25 Schentag Jerome J Vésicules de cholestosome pour l'incorporation de molécules dans des chylomicrons
US20140301974A1 (en) 2009-02-03 2014-10-09 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2014179983A1 (fr) 2013-05-10 2014-11-13 北京华金瑞清生物医药技术有限公司 Procédé de modification d'une protéine non-anticorps pour générer une molécule de liaison, produit généré, et agoniste du récepteur glp-1 à action prolongée
WO2014202727A1 (fr) 2013-06-20 2014-12-24 Novo Nordisk A/S Dérivés de glp-1 et utilisations associées
US20150011462A1 (en) 2013-07-04 2015-01-08 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
AU2014277804A1 (en) 2001-07-31 2015-01-22 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
WO2015022400A1 (fr) 2013-08-15 2015-02-19 Novo Nordisk A/S Dérivés de glp-1 et utilisations de ceux-ci
US20150125431A1 (en) 2012-05-03 2015-05-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
US20150164995A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 Peptide Analogues as Dual GLP-1/GIP Agonists
US20150166627A1 (en) 2013-12-13 2015-06-18 Sanofi Dual GLP-1/GIP Receptor Agonists
US20150164996A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
US20150166625A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 Peptide Analogues
US20150164997A1 (en) 2013-12-13 2015-06-18 Sanofi Dual GLP-1/Glucagon Receptor Agonists
WO2015086731A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine-4 en tant qu'agonistes mixtes des récepteurs glp-1/glucagon
WO2015095406A1 (fr) 2013-12-18 2015-06-25 The California Institute For Biomedical Research Agents thérapeutiques modifiés, conjugués lipide-peptide agrafés, et compositions les comprenant
WO2015132599A1 (fr) 2014-03-06 2015-09-11 Imperial Innovations Limited Analogues d'hormone peptidique pouvant être dérivés du préproglucagon
US20150306181A1 (en) 2012-02-06 2015-10-29 Board Of Regents Of The University Of Nebraska Delivery of biotherapeutics to the brain
WO2015188132A1 (fr) 2014-06-06 2015-12-10 The California Institute For Biomedical Research Procédés de construction de protéines de fusion d'immunoglobuline à terminaison amino et leurs compositions
US20150376256A1 (en) 2011-06-22 2015-12-31 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2016011335A1 (fr) 2014-07-17 2016-01-21 Jerome Schentag Activation de la voie endogène des hormones contrôlant le frein iléal pour la régénération des organes, ainsi que compositions, méthodes de traitement, outils diagnostiques et systèmes de régulation associés
US20160015788A1 (en) 2014-07-15 2016-01-21 Lancaster University Business Enterprises Limited Treatment of neurological diseases
US20160137698A1 (en) 2010-05-21 2016-05-19 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
WO2016083499A1 (fr) 2014-11-27 2016-06-02 Novo Nordisk A/S Dérivés de glp-1 et leurs utilisations
WO2016097108A1 (fr) 2014-12-17 2016-06-23 Novo Nordisk A/S Dérivés de glp-1 et utilisations associées
US20160287713A1 (en) 2013-09-13 2016-10-06 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2016162127A1 (fr) 2015-04-08 2016-10-13 Polyphor Ag Peptidomimétiques à squelette cyclisé
CN106110325A (zh) 2016-06-08 2016-11-16 上海朗安生物技术有限公司 一种新型 glp‑1 受体激动剂的制备方法及其在神经退行性疾病治疗领域的应用
WO2016198628A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp -1/glucagon
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
WO2016205488A1 (fr) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Agents thérapeutiques modifiés et compositions associées
US10508131B2 (en) 2006-12-14 2019-12-17 Bolder Biotechnology, Inc. Cysteine analogs of exendin-4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786590A (zh) * 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
US20210353710A1 (en) * 2020-03-05 2021-11-18 The Johns Hopkins University Glp-1r agonist and methods of treatment

Patent Citations (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137666A1 (fr) 1998-12-07 2001-10-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues glp-1
KR20020001719A (ko) 1999-01-14 2002-01-09 마크 엠. 폴렛타 글루카곤 억제 방법
WO2000069911A1 (fr) 1999-05-17 2000-11-23 Conjuchem, Inc. Peptides insulinotropes a longue duree d'action
WO2002016430A2 (fr) 2000-08-24 2002-02-28 Thomas Jefferson University Nouveau peptide possedant des effets sur la sante cerebrale
US20050222036A1 (en) 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
WO2003011892A2 (fr) 2001-07-31 2003-02-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendine-4, analogues peptidiques et utilisations associees
US20040242853A1 (en) 2001-07-31 2004-12-02 Nigel Greig Glp-1 exendin-4 peptide analogs and uses thereof
AU2014277804A1 (en) 2001-07-31 2015-01-22 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
WO2004022004A2 (fr) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation
US20050009742A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
EP1594529A2 (fr) 2003-02-19 2005-11-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Analogues de glp-1
US20060286066A1 (en) 2003-06-30 2006-12-21 Domantis Limited Pegylated immunoglobulin variable region polypeptides
WO2005023862A2 (fr) 2003-08-07 2005-03-17 Zymogenetics, Inc. Preparations homogenes d'il-28 et d'il-29
US20070027306A1 (en) 2004-02-09 2007-02-01 Rosen Craig A Albumin fusion proteins
WO2005077042A2 (fr) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Proteines hybrides d'albumine
WO2006042848A2 (fr) 2004-10-18 2006-04-27 Novo Nordisk A/S Conjugues d'hormones de croissance
AU2012202972A1 (en) 2005-09-22 2012-06-14 Biocompatibles Uk Ltd GLP-1 fusion peptides, their production and use
EP1767545A1 (fr) 2005-09-22 2007-03-28 Biocompatibles UK Limited Polypeptides de fusion de glp-1 (peptide 1 de type glucagon) ayant une resistance accrue a la peptidase
WO2007075534A2 (fr) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Conjugues polymeres de glp-1
AU2013201640A1 (en) 2006-04-14 2013-04-11 Mannkind Corporation Glucagon-like peptide 1(GLP-1) pharmaceutical formulations
EP1854455A1 (fr) 2006-05-10 2007-11-14 Biocompatibles UK Limited Microcapsules sphériques contenant des peptides du type GLP-1, leur production et leur utilisation
KR20070115602A (ko) 2006-06-01 2007-12-06 이강춘 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도
EP2057189A1 (fr) 2006-08-25 2009-05-13 Novo Nordisk A/S Composés d'exendine-4 acylée
CN101195612A (zh) 2006-12-05 2008-06-11 中国科学院上海药物研究所 一类具有取代环丁烷结构的化合物、及其制备方法和医学用途
US10508131B2 (en) 2006-12-14 2019-12-17 Bolder Biotechnology, Inc. Cysteine analogs of exendin-4
WO2008130066A1 (fr) 2007-04-20 2008-10-30 Kang Choon Lee Exendine mono-modifiee par polyethylene glycol ou ses derives et utilisations associees
WO2008148839A2 (fr) 2007-06-08 2008-12-11 Ascendis Pharma As Conjugués polymères transitoires longue durée de l'exendine
WO2010080578A1 (fr) 2008-12-18 2010-07-15 Phasebio Pharmaceuticals, Inc. Protéines biologiquement actives pouvant être activées par peptidase
US20100323956A1 (en) 2009-02-03 2010-12-23 Amunix, Inc. Glucose-regulating polypeptides and methods of making and using same
US20140301974A1 (en) 2009-02-03 2014-10-09 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2010121559A1 (fr) 2009-04-23 2010-10-28 派格生物医药(苏州)有限公司 Nouveau variant d'exendine et son conjugué
US20120196795A1 (en) 2009-04-23 2012-08-02 Pegbio Co., Ltd. Novel exendin variant and conjugate thereof
WO2011003007A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azabicycloalcane-indole et d’azabicycloalcane-pyrrolo-pyridine, procédés de préparation, et utilisation de ceux-ci
WO2011000095A1 (fr) 2009-07-02 2011-01-06 Angiochem Inc. Conjugués peptidiques multimères et leurs utilisations
KR20110007362A (ko) 2009-07-16 2011-01-24 성균관대학교산학협력단 엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법
US20140187490A1 (en) 2009-08-07 2014-07-03 Rose Pharma A/S Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome
EP2505941A1 (fr) 2009-11-25 2012-10-03 Daikin Industries, Ltd. Dispositif de réfrigération pour contenant
WO2011075393A2 (fr) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
US20130281373A1 (en) 2010-05-05 2013-10-24 Boehringer Ingelheim International Gmbh Combination therapy
WO2011143209A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone
US20130116172A1 (en) 2010-05-13 2013-05-09 Marcadia Biotech, Inc. Glucagon superfamily peptides exhbiting g protein coupled receptor activity
US20160137698A1 (en) 2010-05-21 2016-05-19 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
WO2012000118A1 (fr) 2010-07-02 2012-01-05 Angiochem Inc. Polypeptides courts contenant des acides aminés d pour conjugués thérapeutiques et leurs utilisations
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
WO2012012352A2 (fr) 2010-07-19 2012-01-26 Amidebio, Llc Peptides et protéines modifiés
EP2621538A2 (fr) 2010-09-28 2013-08-07 Amylin Pharmaceuticals, LLC Polypeptides génétiquement modifiés ayant une durée d'action renforcée
US20150376256A1 (en) 2011-06-22 2015-12-31 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2012177444A2 (fr) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon et du récepteur du gpl-1
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
US20130217622A1 (en) 2011-06-28 2013-08-22 B & L Delipharm, Corp. Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical compostion for preventing or treating diabetes, containing same as active ingredient
WO2013002580A2 (fr) 2011-06-28 2013-01-03 정재경 Analogue d'exendine-4 pégylé par du polyéthylène glycol ou un dérivé de celui-ci, son procédé de préparation et composition pharmaceutique pour prévenir ou traiter le diabète, le contenant en tant que principe actif
US20170189545A1 (en) * 2011-06-28 2017-07-06 Theraly Pharmaceuticals Inc. Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient
WO2013004983A1 (fr) 2011-07-04 2013-01-10 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
WO2013009545A1 (fr) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Polypeptides génétiquement modifiés ayant une durée d'action accrue avec une immunogénéicité réduite
US20130116179A1 (en) 2011-09-01 2013-05-09 University Of Ulster Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013051938A2 (fr) 2011-10-07 2013-04-11 Lanthiopep B.V. Analogues peptidiques cycliques de glp-1 ou de peptides apparentés à glp-1 et leurs utilisations
EP2578599A1 (fr) 2011-10-07 2013-04-10 LanthioPep B.V. Analogues cycliques de GLP-1 et peptides de type GLP-1
US20130157934A1 (en) 2011-11-17 2013-06-20 Indiana University Research And Technology Corporation Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity
US20150306181A1 (en) 2012-02-06 2015-10-29 Board Of Regents Of The University Of Nebraska Delivery of biotherapeutics to the brain
EP2630965A1 (fr) 2012-02-24 2013-08-28 Curatis Pharma GmbH Polypeptide pour la protection contre la neurodégénérescence chez les patients souffrant de la sclérose latérale amyotrophique
WO2013148966A1 (fr) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Administration transmuqueuse de polypeptides génétiquement modifiés
WO2013148871A1 (fr) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Polypeptides génétiquement modifiés
US20150125431A1 (en) 2012-05-03 2015-05-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
WO2013192130A1 (fr) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogues du glucagon présentant une activité sur le récepteur du gip
WO2014036323A1 (fr) 2012-08-29 2014-03-06 Mannkind Corporation Méthode et composition pour traiter l'hyperglycémie
WO2014041375A1 (fr) 2012-09-17 2014-03-20 Imperial Innovations Limited Analogues peptidiques du glucagon et du glp1
US20130303436A1 (en) 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
US20160101158A1 (en) 2012-12-06 2016-04-14 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
WO2014096145A1 (fr) 2012-12-21 2014-06-26 Sanofi Dérivés de l'exendine 4 utilisés comme agonistes de glp1/gip ou de glp1/gip/glucagon
WO2014110090A1 (fr) 2013-01-08 2014-07-17 Jerome Schentag Activation de la voie de l'hormone endogène du frein iléal pour la régénérescence d'un organe et des compositions associées, méthodes de traitement, diagnostics, et systèmes de régulation
WO2014131815A1 (fr) 2013-03-01 2014-09-04 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Peptides pour utilisation dans le traitement topique de maladies neurodégénératives rétiniennes, en particulier à des stades précoces de la rétinopathie diabétique et d'autres maladies rétiniennes dans lesquelles la neurodégénérescence joue un rôle essentiel
WO2014152795A2 (fr) 2013-03-14 2014-09-25 Schentag Jerome J Vésicules de cholestosome pour l'incorporation de molécules dans des chylomicrons
WO2014179983A1 (fr) 2013-05-10 2014-11-13 北京华金瑞清生物医药技术有限公司 Procédé de modification d'une protéine non-anticorps pour générer une molécule de liaison, produit généré, et agoniste du récepteur glp-1 à action prolongée
WO2014202727A1 (fr) 2013-06-20 2014-12-24 Novo Nordisk A/S Dérivés de glp-1 et utilisations associées
US20150011462A1 (en) 2013-07-04 2015-01-08 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
WO2015022400A1 (fr) 2013-08-15 2015-02-19 Novo Nordisk A/S Dérivés de glp-1 et utilisations de ceux-ci
US20160287713A1 (en) 2013-09-13 2016-10-06 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US20150164995A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 Peptide Analogues as Dual GLP-1/GIP Agonists
US20150164996A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086731A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine-4 en tant qu'agonistes mixtes des récepteurs glp-1/glucagon
US20150164997A1 (en) 2013-12-13 2015-06-18 Sanofi Dual GLP-1/Glucagon Receptor Agonists
US20150166625A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 Peptide Analogues
US20150166627A1 (en) 2013-12-13 2015-06-18 Sanofi Dual GLP-1/GIP Receptor Agonists
WO2015095406A1 (fr) 2013-12-18 2015-06-25 The California Institute For Biomedical Research Agents thérapeutiques modifiés, conjugués lipide-peptide agrafés, et compositions les comprenant
WO2015132599A1 (fr) 2014-03-06 2015-09-11 Imperial Innovations Limited Analogues d'hormone peptidique pouvant être dérivés du préproglucagon
WO2015188132A1 (fr) 2014-06-06 2015-12-10 The California Institute For Biomedical Research Procédés de construction de protéines de fusion d'immunoglobuline à terminaison amino et leurs compositions
US20160015788A1 (en) 2014-07-15 2016-01-21 Lancaster University Business Enterprises Limited Treatment of neurological diseases
WO2016011335A1 (fr) 2014-07-17 2016-01-21 Jerome Schentag Activation de la voie endogène des hormones contrôlant le frein iléal pour la régénération des organes, ainsi que compositions, méthodes de traitement, outils diagnostiques et systèmes de régulation associés
WO2016083499A1 (fr) 2014-11-27 2016-06-02 Novo Nordisk A/S Dérivés de glp-1 et leurs utilisations
WO2016097108A1 (fr) 2014-12-17 2016-06-23 Novo Nordisk A/S Dérivés de glp-1 et utilisations associées
WO2016162127A1 (fr) 2015-04-08 2016-10-13 Polyphor Ag Peptidomimétiques à squelette cyclisé
WO2016198628A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp -1/glucagon
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
WO2016205488A1 (fr) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Agents thérapeutiques modifiés et compositions associées
CN106110325A (zh) 2016-06-08 2016-11-16 上海朗安生物技术有限公司 一种新型 glp‑1 受体激动剂的制备方法及其在神经退行性疾病治疗领域的应用

Non-Patent Citations (67)

* Cited by examiner, † Cited by third party
Title
Aisen, et al., "A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study", Neurology, 54:588-93 (2000).
Aviles-Olmos, et al., "Exenatide and the treatment of patients with Parkinson's disease", J Clin Invest, 123(6):2730-6 (2013).
Ban, et al., "Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor-Dependent and -Independent Pathways", Circulation, 2340-2350 (2008).
Berendsen, "A glimpse of the holy grail", Science 282:642-3 (1998).
Bomba, et al., "Exanatide promotes cognitive enhancement and poitive brain metabolic changes in PS1-KI mice but has no effets in 3xTg-AD animals", Cell Death & Disease, 4(5):e612 (2013).
Bradley, et al., Limits of cooperativity in a structurally modular protein: Response of the notch ankyrin domain to analogous alanine substitutions in each repeat, J Mol Biol, 324:373-86 (2002).
Byetta package insert, Amylin Pharmaceuticals, 2005. *
Calsolaro, et al., "Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases", CNS Drugs, 29:1023-1039 (2015).
Darsalia, et al., "Exendin-4 Reduces Ischemic Brain injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization", PLOS One, 9(8):e103114 (2014).
Davidson, "Advances in therapy for type 2 GLP-1 receptor agonists and DPP-4 inhibitors", Cleveland Clinic J Med., 76: Supp 5 (2009).
De Jong, et al., "No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial", PLoS One, 23:e1475 (2008).
Definition of Analouge and Derivative, On-line medical Dictionary, accessed Mar. 5, 2000.
Definition of Dimer, thefreedictionary.com, 2 pages, accessed Dec. 8, 2014.
Definition of Trimer, thefreedictionary.com, 2 pages, accessed Dec. 8, 2014.
Dellavalle, et al., "GLP-1 improves neuropathology after murine cold lesion brain trauma", Annals of Clinical and Translational Neurology, 1(9):721-7323 (2014).
Diabetes, Diabetes sympotoins, The Mayo Clinic,https:// www.mayoclinic.org/diseases-conditions/diabetex/in-depth/diabetes-symptoms/art, accessed Dec. 9, 2014.
Farber, et al., "C1q, the recognition subcomponent of the classical pathway of complement, drives microglial activation", J Neurosci Res., 87(3):644-52 (2009).
Gold, et al., "Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study", Dement Geriatr Cogn Disord., 30:131-46 (2010).
Gong, et al., "Research paper: Site-specific PeGylation of exenatide analogues markedly improved their glucoregulatory activity", British J Pharma., 399-412 (2011).
Gong, Nian et al, "Site specific pegylation of exenatide analogues markedly improved their glucoregulatory activity." Brit. J. Pharmacol. (2011) 163, p. 399-412. *
Grey, Madison T. and Woulf, John M.; "Striatal blood-brain barrier permeability in parkinson's disease." J. Cerebral Blood Flow and Metab. (2015) 35 p. 747-750. *
Groeneveld, et al., "potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus", J. of Diabetes Investigation, 7(1):5-16 (2016).
Guadagno, et al., "Microglia-derived TNFα induces apoptosis in neural precursor cells via transcriptional activation of the Bcl-2 family member Puma", Cell Death and Disease, 4:e538 (2013).
Hansen, et al., "Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease", 11(7):e0158205 (2016).
Harkavyi, et al., "Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease", Journal of Neuroinflammation, 5(19):1-9 (2008).
Harris and Chess, "Effect of pegylation on pharmaceuticals", Nat Rev Drug Discov, 2(3):214-21 (2003).
Hernandez, et al., "Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes", Diabetes, 65:172-187 (2015).
Hirsch, et al., "Neuroinflammation in Parkinson's disease: a target for neuroprotection", Lancet Neurol, 8:382-97 (2009).
Holscher, "Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases", J Endocrinol, 221(1): T31-41 (2014).
Hölscher, Christian; "Drugs developed for treatment of diabetes show protective effects in alzheimer's and parkinson's diseases." Acta Physiol. Sinica (2014) 66(5) p. 497-510. *
Hou, et al., "Liraglutide, a long-acting GLP-1 mimetic, and its metabolic attenuate inflammation after intracerebral hemorrhage", Journal of Cerebral Flow & Metabolism 32:2201-2210 (2012).
International Search Report for corresponding PCT application PCT/US2016/68378 dated Apr. 21, 2017.
Iwai, et al., "Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents", Journal of Neuroscience Research, (2014).
Kappe, et al., "GLP-1 secretion by microglial cells and decreased CNS expression in obesity", Journal of Neuro Inflammation, 9(276):1-10 (2012).
Kashihara, Kenich; "Weight loss in parkinson's disease." J. Neurol. (2006) 253 (suppl7) p. VIII-38-VII/41. *
Kim, et al., "Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics", Bioconjug Chem., 22(4):625-32 (2011).
Kim, et al., "Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects", Bioconjug Chem., 23(11):2214-20 (2012).
Lang and Lozano, "Parkinson's disease. Second of two parts", N Engl J Med, 339(16):1130-43 (1998).
Le Tourneau, Christophe et al, "Dose escalation methods in phase I clinical cancer trials." J. Nat. Cancer Inst. (2009) 101 p. 708-720. *
Luk, et al., "Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice", Science, 338(6109):949-53 (2012).
Ma, et al., "Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice", Journal of Neurochemistry, 135(2):301-308 (2015).
Martin, et al., "Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease", Diabetes, American Diabetes Association, 58(2):318-328 (2009).
Meier, "GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus", Nat Rev Endocrinol., 8(12):728-42 (2012).
Mondragon, Angeles et al; "Divergent effects of liraglutide, exendin-4, and stagliptin on beta cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia." PLOSOne (Aug. 2014) 9(8) e104873. *
Montrose-Rafizadeh, et al., "Pancreatic Glucaon-Like Peptide-1 Receptor Couples to Multiple G Proteins and Activates Mitogen-Activated Protein Kinase Pathways in Chinese Hamster Ovary Cells", Endocrinology, 140(3):1132-1140 (1999).
Nagatsua and Sawadab, "L-dopa therapy for Parkinson's disease: past, present, and future", Parkinsonism Relat Disord, 15 Suppl (1):S3-8 (2009).
Ngo, et al., "Computational complexity", Protein Structure Protection and the Lecinthal Paradox, pp. 491-494 (1994).
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators, "Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial", Lancet Neurol., 14(8):795-803 (2015).
Pardridge, "The blood-brain barrier: bottleneck in brain drug development", NeuroRx 2(1): 3-14 (2005).
Partial English Translation of Abstract of Journal of Clinical and Experimental Medicine, 241(7):501-506 (2012).
Patrone, et al., "Diabetes drugs and neurological disorders; new views and therapeutic possibilities", Diabetes & Endocrinology, 2(3):256-262 (2014).
Perry, et al., "Microglial priming in neurodegenerative disease", Nat Rev Neurol.,10:217-24 (2014).
Rudinger, "Peptide Hormones", JA Parsons, Ed pp. 1-7 (1976).
Saijo, et al., "A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death", Cell, 137:47-59 (2009).
Sanchez-Guajardo, et al., "The relation between α-synuclein and microglia in Parkinson's disease: Recent developments", Neuroscience, 302:47-58 (2015).
Sandyk, Reuven; "The relationship between diabetes mellitus and parkinson's disease." Intern. J. Neuroscience (1993) 69 p. 125-130. *
Schernhammer, et al., "Diabetes and the Risk of Developing Parkinson's Disease in Denmark", Diabetes Care, 34:1102-1108 (2011).
Shannon, Richard P.; "Dpp-4 inhibition and neuroprotection: do mechanisms matter?" Diabetes (2013) 62 p. 1029-1031. *
Sigma, "Design custom peptides", Sigma and Genosys, pp. 1-2 (2004).
Simuni and Brundin, "Is exenatide the next big thing in Parkinson's disease", J Parkinsons Dis., 4(3):345-7 (2014).
Taimr, et al., "Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis", Hepatology, 37(1):87-95 (2003).
Voet, "Abnormal hemoglobins", Biochemistry, (2):235-41 (1995).
Wahlqvist, et al., "Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort", Parkinsonism and Related Disorders, 18:753-758 (2012).
Xue, "Exendin-4 treatments of nonobase diabetic mice increases beta-cell proliferation and fractional insulin reactive area", J Diabetes Complic., 24:163-7 (2010).
Yu, et al., "Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates", Sci. Transl. Med., 6(261):261ra154 (2014).
Yun, et al., "Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease", Nature Medicine, 24(7):931-938 (2018).
Yusta, et al., "GLP-1 receptor activation improves b cell function and survival following induction of endoplasmic reticulum stress", Cell Metabolism, 4:391-406 (2006).

Also Published As

Publication number Publication date
EA201891469A1 (ru) 2018-12-28
EP3393496A1 (fr) 2018-10-31
CN108697768B (zh) 2022-07-22
DK3393496T3 (en) 2023-11-13
ES2968038T3 (es) 2024-05-06
AU2016379403B2 (en) 2020-03-12
US20220111010A1 (en) 2022-04-14
AU2016379403A1 (en) 2018-07-19
EP3393496A4 (fr) 2019-07-31
CN108697768A (zh) 2018-10-23
KR20180096733A (ko) 2018-08-29
JP2019500369A (ja) 2019-01-10
LT3393496T (lt) 2023-12-11
JP7026044B2 (ja) 2022-02-25
PL3393496T3 (pl) 2024-04-22
WO2017112889A1 (fr) 2017-06-29
JP2020059735A (ja) 2020-04-16
EP3393496B1 (fr) 2023-10-11
CA3009506A1 (fr) 2017-06-29
US20180369340A1 (en) 2018-12-27
KR102508651B1 (ko) 2023-03-13

Similar Documents

Publication Publication Date Title
US20220111010A1 (en) Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
JP6921006B2 (ja) 老化関連症状を治療するための方法および組成物
KR101921085B1 (ko) 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
JP6258197B2 (ja) 網膜疾患の治療方法
KR101986486B1 (ko) 신경퇴행성 질환의 치료에 사용하기 위한 약제학적 조성물
US9125862B2 (en) Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor
BR112019023116A2 (pt) fragmentos de cdnf e manf do terminal c, composições farmacêuticas que os compreendem e usos dos mesmos
JP6262661B2 (ja) 筋萎縮性側索硬化症治療剤
KR20190034546A (ko) TATκ-CDKL5 융합 단백질, 그의 조성물, 제형 및 용도
JP2006511468A (ja) 内因性エリスロポエチンの組織保護活性を維持する長期作用性エリスロポエチン
WO2009029508A1 (fr) Cathéter intracrânien et procédés d'utilisation
JP2007523196A (ja) Ｎｔ−４／５を用いて肥満または糖尿病を処置する方法
US20060122116A1 (en) Treatment for disorders of the peripheral nervous system
EA043417B1 (ru) АГОНИСТ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ GLP-1r КАК ТЕРАПИЯ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И НЕЙРОДЕГЕНЕРАТИВНЫХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ
KR20130021315A (ko) Ｄｋｋ2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
JP6912072B2 (ja) 前頭側頭型認知症の予防又は治療用医薬
BR112020019696A2 (pt) Fragmentos de cdnf e manf do terminal c, composições farmacêuticas que os compreendem e usos dos mesmos
US10993993B2 (en) Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用
JP2021158953A (ja) 神経細胞の軸索の伸展剤
CN117836330A (zh) 一种改进的glp-1受体激动剂的融合蛋白和应用

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: THE JOHNS HOPKINS UNIVERSITY, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, SEULKI;DAWSON, TED M.;KO, HAN SEOK;AND OTHERS;SIGNING DATES FROM 20180426 TO 20180614;REEL/FRAME:046509/0457

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

AS Assignment

Owner name: THE JOHNS HOPKINS UNIVERSITY, MARYLAND

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE LAST IVENTORS NAME SHOULD BE MAGDALENA SCULLY PREVIOUSLY RECORDED AT REEL: 046509 FRAME: 0457. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:LEE, SEULKI;DAWSON, TED M.;KO, HAN SEOK;AND OTHERS;SIGNING DATES FROM 20180426 TO 20180614;REEL/FRAME:057649/0809

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction